These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

728 related articles for article (PubMed ID: 28138040)

  • 21. Rapid and Sustained Antidepressant Action of the mGlu2/3 Receptor Antagonist MGS0039 in the Social Defeat Stress Model: Comparison with Ketamine.
    Dong C; Zhang JC; Yao W; Ren Q; Ma M; Yang C; Chaki S; Hashimoto K
    Int J Neuropsychopharmacol; 2017 Mar; 20(3):228-236. PubMed ID: 27765808
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Impact of subanesthetic doses of ketamine on AMPA-mediated responses in rats: An in vivo electrophysiological study on monoaminergic and glutamatergic neurons.
    El Iskandrani KS; Oosterhof CA; El Mansari M; Blier P
    J Psychopharmacol; 2015 Jul; 29(7):792-801. PubMed ID: 25759403
    [TBL] [Abstract][Full Text] [Related]  

  • 23. MGS0039: a potent and selective group II metabotropic glutamate receptor antagonist with antidepressant-like activity.
    Chaki S; Yoshikawa R; Hirota S; Shimazaki T; Maeda M; Kawashima N; Yoshimizu T; Yasuhara A; Sakagami K; Okuyama S; Nakanishi S; Nakazato A
    Neuropharmacology; 2004 Mar; 46(4):457-67. PubMed ID: 14975669
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Ketamine for Treatment-Resistant Depression: a New Advocate.
    Pérez-Esparza R
    Rev Invest Clin; 2018; 70(2):65-7. PubMed ID: 29718013
    [TBL] [Abstract][Full Text] [Related]  

  • 25. mGlu2/3 receptor antagonists.
    Chaki S
    Adv Pharmacol; 2019; 86():97-120. PubMed ID: 31378257
    [TBL] [Abstract][Full Text] [Related]  

  • 26. N-(4-((2-(trifluoromethyl)-3-hydroxy-4-(isobutyryl)phenoxy)methyl)benzyl)-1-methyl-1H-imidazole-4-carboxamide (THIIC), a novel metabotropic glutamate 2 potentiator with potential anxiolytic/antidepressant properties: in vivo profiling suggests a link between behavioral and central nervous system neurochemical changes.
    Fell MJ; Witkin JM; Falcone JF; Katner JS; Perry KW; Hart J; Rorick-Kehn L; Overshiner CD; Rasmussen K; Chaney SF; Benvenga MJ; Li X; Marlow DL; Thompson LK; Luecke SK; Wafford KA; Seidel WF; Edgar DM; Quets AT; Felder CC; Wang X; Heinz BA; Nikolayev A; Kuo MS; Mayhugh D; Khilevich A; Zhang D; Ebert PJ; Eckstein JA; Ackermann BL; Swanson SP; Catlow JT; Dean RA; Jackson K; Tauscher-Wisniewski S; Marek GJ; Schkeryantz JM; Svensson KA
    J Pharmacol Exp Ther; 2011 Jan; 336(1):165-77. PubMed ID: 20947638
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Metabotropic glutamate receptors regulate cortical gamma hyperactivities elicited by ketamine in rats.
    Hiyoshi T; Hikichi H; Karasawa J; Chaki S
    Neurosci Lett; 2014 May; 567():30-4. PubMed ID: 24680852
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Mapping the central effects of (±)-ketamine and traxoprodil using pharmacological magnetic resonance imaging in awake rats.
    Tang H; Kukral D; Li YW; Fronheiser M; Malone H; Pena A; Pieschl R; Sidik K; Tobon G; Chow PL; Bristow LJ; Hayes W; Luo F
    J Psychopharmacol; 2018 Feb; 32(2):146-155. PubMed ID: 29378483
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The role of mGlu
    Pałucha-Poniewiera A
    Pharmacol Biochem Behav; 2022 Oct; 220():173454. PubMed ID: 36038006
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Group II metabotropic and alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionate (AMPA)/kainate glutamate receptors regulate the deficit in brain reward function associated with nicotine withdrawal in rats.
    Kenny PJ; Gasparini F; Markou A
    J Pharmacol Exp Ther; 2003 Sep; 306(3):1068-76. PubMed ID: 12805481
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Role of AMPA receptor stimulation and TrkB signaling in the antidepressant-like effect of ketamine co-administered with a group II mGlu receptor antagonist, LY341495, in the forced swim test in rats.
    Pałucha-Poniewiera A; Podkowa K; Pilc A
    Behav Pharmacol; 2019 Sep; 30(6):471-477. PubMed ID: 30724804
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Negative allosteric modulation of metabotropic glutamate receptor 5 results in broad spectrum activity relevant to treatment resistant depression.
    Hughes ZA; Neal SJ; Smith DL; Sukoff Rizzo SJ; Pulicicchio CM; Lotarski S; Lu S; Dwyer JM; Brennan J; Olsen M; Bender CN; Kouranova E; Andree TH; Harrison JE; Whiteside GT; Springer D; O'Neil SV; Leonard SK; Schechter LE; Dunlop J; Rosenzweig-Lipson S; Ring RH
    Neuropharmacology; 2013 Mar; 66():202-14. PubMed ID: 22551786
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Activation of the mTOR signaling pathway in the antidepressant-like activity of the mGlu5 antagonist MTEP and the mGlu7 agonist AMN082 in the FST in rats.
    Pałucha-Poniewiera A; Szewczyk B; Pilc A
    Neuropharmacology; 2014 Jul; 82():59-68. PubMed ID: 24631968
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Role of Serotonergic System in the Antidepressant Actions of mGlu2/3 Receptor Antagonists: Similarity to Ketamine.
    Chaki S; Fukumoto K
    Int J Mol Sci; 2019 Mar; 20(6):. PubMed ID: 30871246
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Lowered brain stimulation reward thresholds in rats treated with a combination of caffeine and N-methyl-D-aspartate but not alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionate or metabotropic glutamate receptor-5 receptor antagonists.
    Bespalov A; Dravolina O; Belozertseva I; Adamcio B; Zvartau E
    Behav Pharmacol; 2006 Jun; 17(4):295-302. PubMed ID: 16914947
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Physiological antagonism between 5-hydroxytryptamine(2A) and group II metabotropic glutamate receptors in prefrontal cortex.
    Marek GJ; Wright RA; Schoepp DD; Monn JA; Aghajanian GK
    J Pharmacol Exp Ther; 2000 Jan; 292(1):76-87. PubMed ID: 10604933
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Ifenprodil rapidly ameliorates depressive-like behaviors, activates mTOR signaling and modulates proinflammatory cytokines in the hippocampus of CUMS rats.
    Yao Y; Ju P; Liu H; Wu X; Niu Z; Zhu Y; Zhang C; Fang Y
    Psychopharmacology (Berl); 2020 May; 237(5):1421-1433. PubMed ID: 32130432
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The metabotropic glutamate (mGLU)2/3 receptor antagonist LY341495 [2S-2-amino-2-(1S,2S-2-carboxycyclopropyl-1-yl)-3-(xanth-9-yl)propanoic acid] stimulates waking and fast electroencephalogram power and blocks the effects of the mGLU2/3 receptor agonist ly379268 [(-)-2-oxa-4-aminobicyclo[3.1.0]hexane-4,6-dicarboxylate] in rats.
    Feinberg I; Schoepp DD; Hsieh KC; Darchia N; Campbell IG
    J Pharmacol Exp Ther; 2005 Feb; 312(2):826-33. PubMed ID: 15383637
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Antidepressant-like actions of the mGlu2/3 receptor antagonist TP0178894 in the chronic social defeat stress model: Comparison with escitalopram.
    Dong C; Tian Z; Fujita Y; Fujita A; Hino N; Iijima M; Hashimoto K
    Pharmacol Biochem Behav; 2022 Jan; 212():173316. PubMed ID: 34968554
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Activation of metabotropic glutamate (mGlu)2 receptors suppresses histamine release in limbic brain regions following acute ketamine challenge.
    Fell MJ; Katner JS; Johnson BG; Khilevich A; Schkeryantz JM; Perry KW; Svensson KA
    Neuropharmacology; 2010 Mar; 58(3):632-9. PubMed ID: 19951716
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 37.